Stockwatch: Earnings Season Inevitabilities
Executive Summary
Johnson & Johnson, Actelion and Roche launched the 2016 third-quarter earnings season with a somewhat mixed opening salvo. The harsh investor response probably reflected an awareness of the inevitability of generic competition.
You may also be interested in...
Stockwatch: Awkward Developments Pricking J.P. Morgan Bubble
The warm fuzzy feeling in life sciences in the week before the J.P. Morgan Healthcare Conference was rudely threatened by clinical trial results from Halozyme and Heron, and negative financial preannouncements from Heron and Teva.
J&J Maintains Strategy For Biosimilar Remicade As Inflectra Nears
The pharma is confident in its current discounting to protect Remicade market share in the US – it still plans to focus on a strategy involving bundling and relying on brand loyalty.
Stockwatch: Third-Quarter Earnings Portents
Negative third-quarter earnings announcements from Vertex and Illumina are not good portents for an end of year life science rally and the absence of helpful positive announcements from Valeant and Gilead does not bode well either.